The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is a huge mover today! About 4.35 million shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 36.20% since April 5, 2016 and is uptrending. It has outperformed by 34.24% the S&P500.
The move comes after 6 months positive chart setup for the $1.91 billion company. It was reported on Nov, 7 by Barchart.com. We have $15.84 PT which if reached, will make NASDAQ:ARIA worth $1.24B more.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage
Out of 7 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 3 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 43% are positive. Ariad Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was initiated by Barclays Capital with “Underweight” on Tuesday, January 19. Leerink Swann initiated the stock with “Outperform” rating in Monday, September 26 report. The firm has “Mkt Perform” rating by JMP Securities given on Tuesday, October 25. The firm earned “Underweight” rating on Friday, July 29 by Barclays Capital. The firm has “Neutral” rating given on Friday, August 7 by JP Morgan. The firm has “Underweight” rating given on Monday, October 24 by JP Morgan. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Underweight” rating by Barclays Capital on Wednesday, May 11. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has “Hold” rating given on Thursday, November 3 by Deutsche Bank. The firm has “Buy” rating given on Wednesday, October 5 by SunTrust.
According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”
Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.73, from 0.67 in 2016Q1. The ratio improved, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Jane Street Gru Lc has invested 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Schwab Charles Inv Mgmt Incorporated last reported 674,330 shares in the company. Westfield Com Limited Partnership, a Massachusetts-based fund reported 10.58 million shares. First Advisors Lp reported 65,108 shares or 0% of all its holdings. Aperio Gp Ltd holds 0% or 23,170 shares in its portfolio. Creative Planning owns 29,000 shares or 0% of their US portfolio. Retail Bank Of America De last reported 146,645 shares in the company. Palo Alto Investors Limited Liability owns 2.54M shares or 1.42% of their US portfolio. Price T Rowe Md holds 74,300 shares or 0% of its portfolio. Edge Wealth Mgmt Ltd Liability Company reported 3,000 shares or 0.01% of all its holdings. Goldman Sachs owns 1.77 million shares or 0% of their US portfolio. Kcg Inc holds 0.02% or 150,016 shares in its portfolio. The New York-based Springbok Cap Mgmt Limited Liability Company has invested 0.01% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Franklin Res owns 19,623 shares or 0% of their US portfolio. Voya Investment Mgmt Ltd Llc last reported 0% of its portfolio in the stock.
Insider Transactions: Since May 12, 2016, the stock had 1 buy, and 11 sales for $3.81 million net activity. CLACKSON TIMOTHY P sold $262,500 worth of stock or 25,000 shares. Radaelli Massimo sold $896,135 worth of stock. Panayiotopoulos Paris bought $199,996 worth of stock or 26,990 shares. $626,039 worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) was sold by LAVIDAS ATHANESE.
More recent Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) news were published by: 247Wallst.com which released: “Why Ariad Pharma Earnings Are So Great Despite a Loss” on November 07, 2016. Also Etfdailynews.com published the news titled: “Bernie Sanders Tweet Causes Ariad Pharma Stock to Plunge 14%” on October 14, 2016. Businesswire.com‘s news article titled: “ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for …” with publication date: October 31, 2016 was also an interesting one.
ARIA Company Profile
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.